SGLT2 Inhibitors and Curcumin Co-loaded Liposomal Formulations as Synergistic Delivery Systems for Heart Failure Therapy
Pharmaceutics · 26.07.2025 · 17 (8) · 969
DOI: 10.3390/pharmaceutics17080969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.07.2025. Verfasst von Bianca-Ștefania Profire und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, 16 University Street, 700115 Iași, Romania. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerul Cercetării și Inovării, Ministry of Research, Innovation, and Digitization.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background/Objectives: As novel synergistic strategy for heart failure (HF), this study explores the formulation and characterization of liposomal systems co-loaded with SGLT2 inhibitors (dapagliflozin—DAPA and empagliflozin—EMPA) and curcumin (Cur).
Methods
To enhance liposomal membrane stability and achieve sustained, controlled drug release, oleanolic acid (OA) was incorporated into the lipid bilayer, while the liposomal surface was coated with polyvinylpyrrolidone (PVP).
Results
The resulting liposomes exhibited favorable physico-chemical properties (particle size ~170 nm, low PDI, negative zeta potential), high encapsulation efficiencies (up to 97%), and spherical morphology as confirmed by STEM. XRD and DSC analyses indicated successful API incorporation and amorphization within the lipid matrix, while PVP coating provided slight improvements in thermal stability. Trehalose proved to be an effective cryoprotectant, preserving liposome integrity after freeze-drying. In vitro release studies demonstrated sustained and delayed drug release, especially in PVP-coated and OA-containing formulations.
Conclusions
All these findings highlight the promise of PVP-coated, OA-stabilized liposomal formulations co-loaded with SGLT2 inhibitors and Cur as biocompatible, multifunctional platforms for targeted HF therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, 16 University Street, 700115 Iași, Romania.
- Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iași, Romania.
- "Petru Poni" Institute of Macromolecular Chemistry, 41A Grigore Ghica-Voda Alley, 700487 Iasi, Romania.
- Institute for Cardiovascular Diseases "Prof. Dr. George I.M. Georgescu", 50 Carol I Boulevard, 700503 Iași, Romania.
- "Sf. Spiridon" Clinical Emergency Hospital, 1 Independence Boulevard, 700111 Iași, Romania.
ORCID-Profile: Bianca-Ștefania Profire, Florentina Geanina Lupașcu, Alexandru Sava, Dana Bejan, Cristian Stătescu, Victorița Șorodoc, Mariana Pinteala, Lenuța Profire
Förderung
- Ministerul Cercetării și Inovării
- Ministry of Research, Innovation, and Digitization
Zitieren
APA
Profire, B. Ș., Lupașcu, F. G., Sava, A., Turin-Moleavin, I. A., Bejan, D., Stătescu, C., Șorodoc, V., Sascău, R. A., Șorodoc, L., Pinteala, M., & Profire, L. (2025). SGLT2 Inhibitors and Curcumin Co-loaded Liposomal Formulations as Synergistic Delivery Systems for Heart Failure Therapy. Pharmaceutics, 17(8), 969. https://doi.org/10.3390/pharmaceutics17080969
Vancouver
Profire BȘ, Lupașcu FG, Sava A, Turin-Moleavin IA, Bejan D, Stătescu C, et al. SGLT2 Inhibitors and Curcumin Co-loaded Liposomal Formulations as Synergistic Delivery Systems for Heart Failure Therapy. Pharmaceutics. 2025;17(8):969. doi:10.3390/pharmaceutics17080969
BibTeX
@article{Profire2025,
author = {Profire, Bianca-Ștefania and Lupașcu, Florentina Geanina and Sava, Alexandru and Turin-Moleavin, Ioana-Andreea and Bejan, Dana and Stătescu, Cristian and Șorodoc, Victorița and Sascău, Radu-Andy and Șorodoc, Laurențiu and Pinteala, Mariana and Profire, Lenuța},
title = {SGLT2 Inhibitors and Curcumin Co-loaded Liposomal Formulations as Synergistic Delivery Systems for Heart Failure Therapy},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {969},
doi = {10.3390/pharmaceutics17080969}
}
EUVIMED